HEPATOSPLENIC T-CELL LYMPHOMA
Clinical trials for HEPATOSPLENIC T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new HEPATOSPLENIC T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for HEPATOSPLENIC T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene therapy trial targets tough T-Cell cancers
Disease control Recruiting nowThis early-stage trial tests a new gene therapy for certain T-cell lymphomas that have come back or not responded to treatment. The therapy uses a patient's own white blood cells, modified to attack cancer cells that carry a protein called CCR4. Up to 60 adults will receive the m…
Matched conditions: HEPATOSPLENIC T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for rare blood cancers: first human trial launches
Disease control Recruiting nowThis study tests a new drug called DR-01 in adults with rare types of leukemia or lymphoma. The goal is to see if it is safe and can shrink tumors. About 200 people will take part in this early-stage trial.
Matched conditions: HEPATOSPLENIC T-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Dren Bio • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise for rare lymphoma in Real-World study
Disease control Recruiting nowThis observational study tracks 100 adults in Spain with CD30-positive peripheral T-cell lymphoma who received brentuximab vedotin plus CHP as their first treatment. Researchers will review medical records to see how long patients live without their cancer getting worse, how well…
Matched conditions: HEPATOSPLENIC T-CELL LYMPHOMA
Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for rare blood cancer: Two-Drug combo trial launches
Disease control Recruiting nowThis phase 3 trial tests whether adding either belinostat or pralatrexate to standard chemotherapy helps people with newly diagnosed peripheral T-cell lymphoma live longer without their cancer getting worse. About 504 participants will be randomly assigned to one of three treatme…
Matched conditions: HEPATOSPLENIC T-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Acrotech Biopharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Massive T-Cell lymphoma database aims to unlock new insights
Knowledge-focused Recruiting nowThis study is creating a large database of information and tissue samples from 1,000 people with T-cell lymphoma. Researchers will use this data to learn more about the disease and how to improve patient outcomes. Participants provide medical information and optional blood and na…
Matched conditions: HEPATOSPLENIC T-CELL LYMPHOMA
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC